Bli medlem
Bli medlem

Du är här

2022-11-28

Scandinavian ChemoTech's Animal Care division signs significant Clinical Evaluation Agreement with The Royal Veterinary College

Vetiqure AB is excited to share the signing of a very important Clinical Evaluation Agreement with The Royal Veterinary College's (RVC) Equine team in London, UK. The RVC is one of the world's leading specialist higher education institutions for veterinary medicine, biosciences and veterinary nursing and was ranked as the world's No 1 veterinary school in the QS World University Rankings 2022. 

The purpose of this agreement is to further study the Tumour Specific Electroporation's (TSE) effect on sarcoids in horses and examine the immunological effects.

The RVC will have access to our vetIQure™ TSE device during a 6-month evaluation period and perform a commercial purchase of treatment kits during this time. In addition to the purchase of the treatment kits, an order for the device will be placed following a successful evaluation.

"We are really excited to be trialing the vetIQure™ TSE device at the Royal Veterinary College. The RVC is a world leader in innovation, and we anticipate this novel treatment will increase the breadth of treatment options we have for sarcoids and other tumours. We are also pleased to be collaborating with Vetiqure in this exciting project."- says Andrew Fiske-Jackson, Lead investigator, Royal Veterinary College

"We are so pleased to have been able to connect with the RVC and sign this evaluation agreement. It is of utmost importance to collect even more clinical data to further back our claim. To be able to do so in collaboration with RVC is a monumental step for our Animal Care division. We look forward to the outcome of this evaluation and to the opportunity to conduct further future collaborative endeavours together." - says Mohan Frick, CEO ChemoTech & Vetiqure

About the Royal Veterinary College

The Royal Veterinary College, London, was built in the parish of St Pancras in 1791, on the current site of The RVC's Camden Campus. RVC is the UK's largest and longest-established independent vet school and is a Member Institution of the University of London. The College offers undergraduate and postgraduate programmes in veterinary medicine, veterinary nursing, and biological sciences, and CPD programmes in veterinary medicine and veterinary nursing. As one of the world's leading specialist veterinary and biological science research institutions, the RVC brings together talented individuals; all of whom share a passion for human and animal health and welfare. The RVC is ranked as the top veterinary school in the world in line with the QS World University Rankings by subject, 2022. lt is a research-led institution with 88% of its research rated as internationally excellent or world-class in the Research Excellence Framework 2021.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,

E-mail:certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se

Författare Cision